Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2010

View Archived Issues

Phase III trial data support safety and tolerability of tafenoquine in malaria prophylaxis

Elevated GDF-15 identified as predictor of mortality in acute reperfused STEMI

GlaxoSmithKline describes potent, orally bioavailable CXCR4 antagonist for HIV-1

Genome-wide RNAi screen reveals drug targets for influenza viruses

Amira Pharmaceuticals describes novel prostaglandin D2 receptor antagonists

New Rho-associated protein kinase inhibitors disclosed

Novel TNF-alpha production inhibitors claimed by sanofi-aventis

PLK-1 inhibitors for the treatment of cancer described by Roche

Monoclonal antibody against integrin alphaV/beta3 reduces atherosclerotic lesions in diabetic pigs

Plant-produced monoclonal antibody protects mice against West Nile virus infection

Noninvasive CMR technique allows assessment of diffuse myocardial fibrosis

GSK reflects on fourth quarter and highlights of 2009

Tioga raises funds for phase III asimadoline trial in D-IBS

Paladin amends R&D agreement with Isotechnika for diagnostic products

Phase II oral interferon trial indicates benefit in preventing influenza-like illness

SurModics to terminate license agreement with Ambrilia Biopharma

Dynavax and GSK select candidate in endosomal TLR inhibitor program

Stem Cell Therapeutics provides update on modified REGENESIS trial

Thallion and LFB sign agreement to develop STEC infection therapy

Immune Targeting Systems secures funds to develop FP-01 universal flu vaccine

FDA accepts for filing Jazz Pharmaceuticals' NDA for sodium oxybate for fibromyalgia

Chugai licenses Roche's Hedgehog pathway inhibitor RG-3616 in Japan

FDA grants priority review to Novartis' Tasigna for newly diagnosed Ph+CML

FDA grants orphan drug status to EntreMed's ENMD-2076 for acute myeloid leukemia

Novel N-type calcium channel blockers claimed by Lectus Therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...